ClinicalTrials.gg

Program

HRS-2189

A development code. Also written as “HRS-2189 Tablet” and “HRS-2189 Tablets”.

In Jiangsu HengRui Medicine's pipeline, KAT6. Its studies are led by Jiangsu HengRui Medicine.

Furthest: phase 1, since Apr 24, 20232 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine21 open or runningphase 1since Apr 24, 2023Apr 24, 2023none ahead
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-2189, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 24, 2023First study: phase 1 study in Advanced Malignant TumorFirst studyNCT05851092 · 60 planned · China
  2. Jun 5, 2026Phase 1 study in Malignant Solid TumorNCT07639905 · 28 enrolled · China

TargetBeta

“KAT6”the company's pipeline, read by Claude · source

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
prifetrastatPfizerphase 310
KAT6A/B Inhibitor BG-75202ruleBeOne Medicinesphase 12
KAT6 Inhibitor OP-3136ruleolema-pharmaceuticals-incphase 11
KAT6/KAT7 Inhibitor PF-08032562rulePfizerphase 11
KAT6/KAT7 Inhibitor IDE574ruleideaya-biosciencesphase 11
HLX97Fosun Pharmaphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07639905Malignant Solid Tumor · China1CompletedAug 6, 202628
NCT05851092Advanced Malignant Tumor · China1RecruitingDec 31, 202560

How it is read

Names in the registry

  • “HRS-2189 Tablet”, 1 entry
  • “HRS-2189 Tablets”, 1 entry

Codes read as this program: HRS2189.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.